1
Test Bank for Psychopharmacology:
Drugs, the Brain and Behavior 4TH
EDITION by Jerrold S. Meyer & Linda F.
Quenzer|978-1605359878 | All Chapters
1-20| LATEST
WWW.THENURSINGMASTERY.COM
Page 1 of 247
,2
TABLE OF CONTENTS
1. CHAPTER 1: Principles of Pharmacology
2. Box 1.1 Pharmacology in Action: Naming Drugs
3. Box 1.2 Pharmacology in Action: Interspecies Drug Dose Extrapolation
4. Box 1.3 Pharmacology in Action: Drug Categories
5. CHAPTER 2: Structure and Function of the Nervous System
6. Box 2.1 The Cutting Edge: Embryonic Stem Cells
7. Box 2.2 Of Special Interest: Astrocytes
8. Box 2.3 The Cutting Edge: Finding Your Way in the Nervous System
9. Box 2.4 Of Special Interest: Neuroendocrine Response to Stress
10.CHAPTER 3: Chemical Signaling by Neurotransmitters and Hormones
11.Box 3.1 Clinical Applications: Orexin-Based Medications: New Approaches
to the Treatment of Sleep Di
12.Box 3.2: Pharmacology in Action: Sex Hormones and Drug Abuse
13.CHAPTER 4: Methods of Research in Psychopharmacology
14.Box 4.1 Pharmacology in Action: Using the Three-Chamber Social
Interaction Test
15.Box 4.2 Clinical Applications: Drug Testing for FDA Approval
16.Box 4.3 Pharmacology in Action: Transgenic Model of Huntington’s
Disease
17.CHAPTER 5: Catecholamines
18.Box 5.1 Clinical Applications: Mutations That Affect Dopamine
19.Box 5.2 The Cutting Edge: Using Molecular Genetics to Study the
Dopaminergic
20.CHAPTER 6: Serotonin
21.Box 6.1 History of Psychopharmacology: “Ecstasy”—Harmless Feel-Good
Drug, Dangerous Neurotoxin
22.Box 6.2 The Cutting Edge: Serotonin and Aggression
23.CHAPTER 7: Acetylcholine
24.Box 7.1 Pharmacology In Action: Botulinum Toxin—Deadly Poison,
Therapeutic Remedy, and Cosmetic Ai
25.Box 7.2 The Cutting Edge: Acetylcholine and Cognitive Function
26.CHAPTER 8: Glutamate and GABA
27.Box 8.1 Clinical Applications: Fragile X Syndrome and Metabotropic
Glutamate Receptor Antagonists: A
28.Box 8.2: Clinical Applications: GABA and Epilepsy
29.GABA also signals using metabotropic GABAB receptors
30.CHAPTER 9: Drug Abuse and Addiction
31.Box 9.1 Of Special Interest: Should the Term Addiction Be Applied to
Compulsive Behavioral Disorders
32.CHAPTER 10: Alcohol
33.Box 10.1 Pharmacology in Action: The Role of Expectation in Alcohol-
WWW.THENURSINGMASTERY.COM
Page 2 of 247
,3 Enhanced Human Sexual Response
34.CHAPTER 11: The Opioids
35.Box 11.1 Clinical Applications: Saving a Life: Naloxone for Opioid
Overdoses
36.Box 11.2 The Cutting Edge: Science in Action
37.Box 11.3 Of Special Interest: The Opioid Epidemic
38.CHAPTER 12: Psychomotor Stimulants: Cocaine, Amphetamine, and
Related Drugs
39.Box 12.1 The Cutting Edge: Neurochemical Mechanisms of Cocaine
Tolerance and Sensitization
40.Box 12.2 Clinical Applications: Psychostimulants and ADHD
41.CHAPTER 13: Nicotine and Caffeine
42.Box 13.1 The Cutting Edge: How Safe Are E-cigarettes?
43.CHAPTER 14: Marijuana and the Cannabinoids
44.Box 14.1 Of Special Interest: Beyond Cannabis: The Rise of Synthetic
Cannabinoids
45.CHAPTER 15: Hallucinogens, PCP, and Ketamine
46.Box 15.1: History of Pharmacology: The Discovery of LSD
47.Box 15.2: Pharmacology In Action: Getting High on Cough Syrup
48.Novel therapeutic applications have been proposed for ketamine
49.CHAPTER 16: Inhalants, GHB, and Anabolic–Androgenic Steroids
50.Box 16.1: Of Special Interest: Anabolic–Androgenic Steroids and “Roid
Rage”
51.CHAPTER 17: Disorders of Anxiety and Impulsivity and the Drugs
Used to Treat These Disorders
52.Box 17.1: The Cutting Edge: Neural Mechanism Responsible for High Tonic
Cell Firing Mediating Anxiet
53.CHAPTER 18: Affective Disorders: Antidepressants and Mood
Stabilizers
54.Box 18.1: The Cutting Edge: Epigenetic Modifications in Psychopathology
and Treatment
55.CHAPTER 19: Schizophrenia: Antipsychotic Drugs
56.Box 19.1: The Cutting Edge: Epigenetic Modifications and Risk for
Schizophrenia
57.Preclinical Models of Schizophrenia
58.Box 19.2: Pharmacology In Action: The Prenatal Inflammation Model of
Schizophrenia
59.CHAPTER 20: Neurodegenerative Diseases
60.Box 20.1 The Cutting Edge: Alzheimer’s Disease: It’s all in your gut???
61.Box 20.2: Pharmacology in Action: Can We Repair or Replace Myelin?
WWW.THENURSINGMASTERY.COM
Page 3 of 247
, 4 Test Bank
to accompany
Psychopharmacology, Third Edition
Meyer • Quenzer
Chapter 1: Principles of Pharmacology
Multiple Choice
1. refer(s) to specific molecular changes that occur when a drug binds
to a particular target site or receptor, whileare the resulting widespread
alterations in function.
a. Drug action; therapeutic effects
b. Side effects; drug effects
c. Therapeutic effects; side effects
d. Drug action; drug effects
ANS: d
Textbook Reference: Pharmacology: The Science of Drug Action
2. After drug administration has occurred, the amount of drug in the blood that
is free to bind at specific target sites is referred to as
a. the therapeutic dose.
b. first-pass effects.
c. bioavailability.
d. ED50.
ANS: c
Textbook Reference: Pharmacokinetic Factors Determining Drug Action
3. The specific molecular changes that occur when a drug binds to a particular
target site or receptor are referred to as
a. drug effects.
b. drug action.
c. side effects.
d. placebo effects.
ANS: b
Textbook Reference: Pharmacology: The Science of Drug Action
4. Which of the following is not a possible explanation for placebo effects?
a. Pavlovian conditioning
b. Genetic variation
c. Drug competition
d. Expectation of outcome
ANS: c
Textbook Reference: Pharmacology: The Science of Drug Action
WWW.THENURSINGMASTERY.COM
Page 4 of 247
Test Bank for Psychopharmacology:
Drugs, the Brain and Behavior 4TH
EDITION by Jerrold S. Meyer & Linda F.
Quenzer|978-1605359878 | All Chapters
1-20| LATEST
WWW.THENURSINGMASTERY.COM
Page 1 of 247
,2
TABLE OF CONTENTS
1. CHAPTER 1: Principles of Pharmacology
2. Box 1.1 Pharmacology in Action: Naming Drugs
3. Box 1.2 Pharmacology in Action: Interspecies Drug Dose Extrapolation
4. Box 1.3 Pharmacology in Action: Drug Categories
5. CHAPTER 2: Structure and Function of the Nervous System
6. Box 2.1 The Cutting Edge: Embryonic Stem Cells
7. Box 2.2 Of Special Interest: Astrocytes
8. Box 2.3 The Cutting Edge: Finding Your Way in the Nervous System
9. Box 2.4 Of Special Interest: Neuroendocrine Response to Stress
10.CHAPTER 3: Chemical Signaling by Neurotransmitters and Hormones
11.Box 3.1 Clinical Applications: Orexin-Based Medications: New Approaches
to the Treatment of Sleep Di
12.Box 3.2: Pharmacology in Action: Sex Hormones and Drug Abuse
13.CHAPTER 4: Methods of Research in Psychopharmacology
14.Box 4.1 Pharmacology in Action: Using the Three-Chamber Social
Interaction Test
15.Box 4.2 Clinical Applications: Drug Testing for FDA Approval
16.Box 4.3 Pharmacology in Action: Transgenic Model of Huntington’s
Disease
17.CHAPTER 5: Catecholamines
18.Box 5.1 Clinical Applications: Mutations That Affect Dopamine
19.Box 5.2 The Cutting Edge: Using Molecular Genetics to Study the
Dopaminergic
20.CHAPTER 6: Serotonin
21.Box 6.1 History of Psychopharmacology: “Ecstasy”—Harmless Feel-Good
Drug, Dangerous Neurotoxin
22.Box 6.2 The Cutting Edge: Serotonin and Aggression
23.CHAPTER 7: Acetylcholine
24.Box 7.1 Pharmacology In Action: Botulinum Toxin—Deadly Poison,
Therapeutic Remedy, and Cosmetic Ai
25.Box 7.2 The Cutting Edge: Acetylcholine and Cognitive Function
26.CHAPTER 8: Glutamate and GABA
27.Box 8.1 Clinical Applications: Fragile X Syndrome and Metabotropic
Glutamate Receptor Antagonists: A
28.Box 8.2: Clinical Applications: GABA and Epilepsy
29.GABA also signals using metabotropic GABAB receptors
30.CHAPTER 9: Drug Abuse and Addiction
31.Box 9.1 Of Special Interest: Should the Term Addiction Be Applied to
Compulsive Behavioral Disorders
32.CHAPTER 10: Alcohol
33.Box 10.1 Pharmacology in Action: The Role of Expectation in Alcohol-
WWW.THENURSINGMASTERY.COM
Page 2 of 247
,3 Enhanced Human Sexual Response
34.CHAPTER 11: The Opioids
35.Box 11.1 Clinical Applications: Saving a Life: Naloxone for Opioid
Overdoses
36.Box 11.2 The Cutting Edge: Science in Action
37.Box 11.3 Of Special Interest: The Opioid Epidemic
38.CHAPTER 12: Psychomotor Stimulants: Cocaine, Amphetamine, and
Related Drugs
39.Box 12.1 The Cutting Edge: Neurochemical Mechanisms of Cocaine
Tolerance and Sensitization
40.Box 12.2 Clinical Applications: Psychostimulants and ADHD
41.CHAPTER 13: Nicotine and Caffeine
42.Box 13.1 The Cutting Edge: How Safe Are E-cigarettes?
43.CHAPTER 14: Marijuana and the Cannabinoids
44.Box 14.1 Of Special Interest: Beyond Cannabis: The Rise of Synthetic
Cannabinoids
45.CHAPTER 15: Hallucinogens, PCP, and Ketamine
46.Box 15.1: History of Pharmacology: The Discovery of LSD
47.Box 15.2: Pharmacology In Action: Getting High on Cough Syrup
48.Novel therapeutic applications have been proposed for ketamine
49.CHAPTER 16: Inhalants, GHB, and Anabolic–Androgenic Steroids
50.Box 16.1: Of Special Interest: Anabolic–Androgenic Steroids and “Roid
Rage”
51.CHAPTER 17: Disorders of Anxiety and Impulsivity and the Drugs
Used to Treat These Disorders
52.Box 17.1: The Cutting Edge: Neural Mechanism Responsible for High Tonic
Cell Firing Mediating Anxiet
53.CHAPTER 18: Affective Disorders: Antidepressants and Mood
Stabilizers
54.Box 18.1: The Cutting Edge: Epigenetic Modifications in Psychopathology
and Treatment
55.CHAPTER 19: Schizophrenia: Antipsychotic Drugs
56.Box 19.1: The Cutting Edge: Epigenetic Modifications and Risk for
Schizophrenia
57.Preclinical Models of Schizophrenia
58.Box 19.2: Pharmacology In Action: The Prenatal Inflammation Model of
Schizophrenia
59.CHAPTER 20: Neurodegenerative Diseases
60.Box 20.1 The Cutting Edge: Alzheimer’s Disease: It’s all in your gut???
61.Box 20.2: Pharmacology in Action: Can We Repair or Replace Myelin?
WWW.THENURSINGMASTERY.COM
Page 3 of 247
, 4 Test Bank
to accompany
Psychopharmacology, Third Edition
Meyer • Quenzer
Chapter 1: Principles of Pharmacology
Multiple Choice
1. refer(s) to specific molecular changes that occur when a drug binds
to a particular target site or receptor, whileare the resulting widespread
alterations in function.
a. Drug action; therapeutic effects
b. Side effects; drug effects
c. Therapeutic effects; side effects
d. Drug action; drug effects
ANS: d
Textbook Reference: Pharmacology: The Science of Drug Action
2. After drug administration has occurred, the amount of drug in the blood that
is free to bind at specific target sites is referred to as
a. the therapeutic dose.
b. first-pass effects.
c. bioavailability.
d. ED50.
ANS: c
Textbook Reference: Pharmacokinetic Factors Determining Drug Action
3. The specific molecular changes that occur when a drug binds to a particular
target site or receptor are referred to as
a. drug effects.
b. drug action.
c. side effects.
d. placebo effects.
ANS: b
Textbook Reference: Pharmacology: The Science of Drug Action
4. Which of the following is not a possible explanation for placebo effects?
a. Pavlovian conditioning
b. Genetic variation
c. Drug competition
d. Expectation of outcome
ANS: c
Textbook Reference: Pharmacology: The Science of Drug Action
WWW.THENURSINGMASTERY.COM
Page 4 of 247
